Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Niravam Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Phase 4 Interventional

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

NCT00635531
View directory record Official record
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Hialeah, Florida • Jacksonville, Florida • North Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

NCT05006079
View directory record Official record
Conditions
Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse
Interventions
Morphine, Alprazolam, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

NCT04802746
View directory record Official record
Conditions
Healthy Study Participants, Participants With Mild Asthma
Interventions
Alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
North Dartmouth, Massachusetts • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

NCT00266409
View directory record Official record
Conditions
Generalized Anxiety Disorder, Panic Disorder
Interventions
Niravam, SSRI/SNRI
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sedative-Anxiolytic Effects on Simulated Driving Performance

NCT03297944
View directory record Official record
Conditions
Psychomotor Impairment
Interventions
Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
Drug
Lead sponsor
Marion Coe
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Opiates and Benzodiazepines on Driving

NCT03447353
View directory record Official record
Conditions
Driving Behavior
Interventions
Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Timothy L. Brown
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

NCT00662259
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Alprazolam (Xanax), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

NCT00829426
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

NCT01188031
View directory record Official record
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

NCT05602818
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed No phase listed Observational

Alprazolam and Eating Behavior in Anorexia Nervosa

NCT01411813
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Not listed
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg

NCT00650299
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-release Tablets 3 mg, Xanax XR® Tablets 3 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 3 Interventional

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
66
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

NCT06293638
View directory record Official record
Conditions
Essential Tremor
Interventions
Alcohol, Alprazolam, Cold Therapy, Peripheral Nerve Stimulation
Drug · Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Phase 4 Interventional

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

NCT00634790
View directory record Official record
Conditions
Panic Disorder
Interventions
alprazolam XR
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
47
States / cities
Little Rock, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg

NCT00647894
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release Tablets 1 mg, Xanax XR Tablets 1 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim

NCT04970342
View directory record Official record
Conditions
Driving Behavior, Driving Under the Influence
Interventions
Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD)
Drug
Lead sponsor
Timothy L. Brown
Other
Eligibility
19 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Alprazolam Abuse Liability

NCT00603980
View directory record Official record
Conditions
Abuse Liability of Staccato Alprazolam
Interventions
Inhaled placebo + oral placebo, Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, Oral alprazolam 1 mg, Oral alprazolam 2 mg, Oral alprazolam 4 m, Oral alprazolam 2 mg qualifying session, Oral placebo qualifying session
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam and Photoparoxysmal Response

NCT02351115
View directory record Official record
Conditions
Epilepsy
Interventions
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Boise, Idaho • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience

NCT07777965
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users
Interventions
Alprazolam (Xanax), Placebo, Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam in Panic Attack

NCT00477451
View directory record Official record
Conditions
Treatment of Induced Panic Attack
Interventions
Inhaled placebo, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, IV doxapram
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 20, 2026, 2:27 PM EDT